We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New POC Malaria Test 12 Times Faster Than Currently Available Laboratory-Based Tests

By LabMedica International staff writers
Posted on 01 Mar 2024

Malaria continues to pose a major global health threat, with approximately 247 million cases and over 600,000 deaths annually, predominantly in sub-Saharan Africa. Particularly alarming is cerebral malaria, a severe form of the disease, which has a high mortality rate, especially among children under five. The existing rapid diagnostic tests (RDTs) for malaria offer a basic positive or negative result, but often fail to detect asymptomatic infections and lack the sensitivity required for early detection of severe cases. More sensitive molecular assays that exist are costly, time-consuming, and need specialized skills and equipment, rendering them unsuitable for widespread application in areas with limited resources. In light of these challenges, researchers have now developed a new test for diagnosing malaria that is both rapid and accurate. This POC rapid malaria test offers a significant improvement over traditional tests and will be especially beneficial for rural areas with limited healthcare facilities.

Researchers at Rice University (Houston, TX, USA) developed a microfluidic point-of-care (mPOC) immunoassay for quantifying a malaria parasite biomarker, Plasmodium falciparum histidine-rich protein 2 (PfHRP2), in whole blood. This device provides dual diagnostic modes to detect PfHRP2 at low and high concentrations, making it versatile for various diagnostic needs, such as identifying asymptomatic infections and predicting disease progression. The test produces results in just 15 minutes, which can be easily accessed via a smartphone app developed by the researchers. Field tests in Malawi revealed that the mPOC immunoassay matches the accuracy of the standard PfHRP2 enzyme-linked immunosorbent assay (ELISA), but is 12 times quicker and simpler to operate. This advancement in malaria diagnostics, especially for cerebral malaria, holds the promise of early detection and prompt treatment of severe cases, potentially saving numerous lives.

“The mPOC immunoassay was designed to be simple, accurate and field-deployable, making it suitable for use in rural and remote health centers in sub-Saharan Africa,” said mechanical engineer Peter Lillehoj of Rice’s Brown School of Engineering who led the research team. “Unlike traditional tests, this device does not require plasma separation, pipetting, complicated sample processing or long incubations, making it easy to use even by minimally trained health care providers.”

“In areas with limited access to health care facilities, our test could be a game-changer,” added Lillehoj. “It can help health care providers quickly identify and treat severe cases, potentially saving lives. By enabling early detection and appropriate management of malaria cases, we can reduce the burden of the disease and improve patient outcomes in Africa and beyond.”

Related Links:
Rice University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.